Regulatory Updates In Brief
This article was originally published in The Gold Sheet
Executive Summary
ISPE discussion paper addresses revalidating legacy products; PDA tackles data integrity; FDA clarifies criteria for comparability protocols; FDA spells out criteria for developing assays for evaluating immunogenicity of therapeutic proteins; FDA sets new policy on grouping supplement; EMA outlines new expectations for sterility testing.